ArticleNature chemistry2018
Asymmetric transfer hydrogenation by synthetic catalysts in cancer cells.
Article in Nature chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 222 citations in OpenAlex.
- A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Expanding the Organoiridium Catalyst Design Space Using Sulfur-Containing Bioisosteres.Inorganic chemistry · 2026Article
- Efficient synthesis of chiral vicinal diamines with four contiguous stereocenters via sequential dynamic kinetic resolution of 2,3-diamino-1,4-diketones.Nature communications · 2026Article
- Metal-Based Therapeutic Approaches for Overcoming Cancer Drug Resistance: Mechanisms, Drug Delivery Strategies, and Clinical Perspectives.Oncology research · 2026Review
- Novel tryptophan 2,3-dioxygenase-targeted ruthenium(ii)-indole complex activates immunotherapyChemical science · 2025Article
- Selective Iridium-Catalyzed Reductive Amination Inside Living Cells.Journal of the American Chemical Society · 2025Article
- A Half-Sandwich Os(II) Glucoconjugated NHC Complex as a Modulator of Amyloid Aggregation.Inorganic chemistry · 2025Article
- Vilsmeier-Haack complex formation by FeTurkish journal of chemistry · 2025Article
- Tumor-targeted glutathione oxidation catalysis with ruthenium nanoreactors against hypoxic osteosarcoma.Nature communications · 2024Article
- Pressure-induced generation of heterogeneous electrocatalytic metal hydride surfaces for sustainable hydrogen transfer.Nature communications · 2024Article
- Biomimetic Chiral Nanomaterials with Selective Catalysis Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- A Transfer Hydrogenation Approach to Activity-Based Sensing of Formate in Living Cells.Journal of the American Chemical Society · 2024Article
- Effect of Ligand Substituents on Spectroscopic and Catalytic Properties of Water-Compatible Cp*Ir-(pyridinylmethyl)sulfonamide-Based Transfer Hydrogenation Catalysts.Inorganic chemistry · 2024Article
- Lewis acid-driven self-assembly of diiridium macrocyclic catalysts imparts substrate selectivity and glutathione tolerance.Chemical science · 2023Article
- Nanocompartment-confined polymerization in living systems.Nature communications · 2023Article
- Variations in Intracellular Organometallic Reaction Frequency Captured by Single-Molecule Fluorescence Microscopy.Angewandte Chemie (International ed. in English) · 2023Article
- Organoiridium Complexes Enhance Cellular Defense Against Reactive Aldehydes Species.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy.Science advances · 2023Article
- Targeting cancer lactate metabolism with synergistic combinations of synthetic catalysts and monocarboxylate transporter inhibitors.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2023Article
- Role of ROS‑mediated autophagy in melanoma (Review).Molecular medicine reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Catalytic anticancer metallodrugs active at low doses could minimize side-effects, introduce novel mechanisms of action that combat resistance and widen the spectrum of anticancer-drug activity. Here we use highly stable chiral half-sandwich organometallic Os(II) arene sulfonyl diamine complexes, [Os(arene)(TsDPEN)] (TsDPEN, N-(p-toluenesulfonyl)-1,2-diphenylethylenediamine), to achieve a highly enantioselective reduction of pyruvate, a key intermediate in metabolic pathways. Reduction is shown both in aqueous model systems and in human cancer cells, with non-toxic concentrations of sodium formate used as a hydride source. The catalytic mechanism generates selectivity towards ovarian cancer cells versus non-cancerous fibroblasts (both ovarian and lung), which are commonly used as models of healthy proliferating cells. The formate precursor N-formylmethionine was explored as an alternative to formate in PC3 prostate cancer cells, which are known to overexpress a deformylase enzyme. Transfer-hydrogenation catalysts that generate reductive stress in cancer cells offer a new approach to cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.